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ABSTRACT: Early osteoarthritis (OA) is poorly understood, but abnormal chondrocyte morphology might be important. We studied IL-1
and pericellular collagen type VI inmorphologically normal and abnormal chondrocytes. In situ chondrocytes within explants from nonde-
generate (grade 0/1) areas of human tibial plateaus (n=21) were ﬂuorescently labeled and visualized [2-photon laser scanningmicroscopy
(2PLSM)]. Normal chondrocytes exhibited a “smooth” membrane surface, whereas abnormal cells were deﬁned as demonstrating >1 cyto-
plasmic process. Abnormal chondrocytes were further classiﬁed by number and average length of cytoplasmic processes/cell. IL-1 or
collagen type VI associated with single chondrocytes were visualized by ﬂuorescence immuno-histochemistry and confocal laser scanning
microscopy (CLSM). Fluorescence was quantiﬁed as the number of positive voxels (i.e., 3D pixels with ﬂuorescence above baseline)/cell.
IL-1-associated ﬂuorescence increased between normal and all abnormal cells in the superﬁcial (99.7±29.8 [11 (72)] vs. 784±382
[15 (132)]; p=0.04, positive voxels/cell) and deep zones (66.5±29.4 [9 (64)] vs. 795±224 [9 (56)]; p=0.006). There was a correlation
(r2 =0.988) between the number of processes/cell (0–5) and IL-1, and an increase particularly with short processes (≤5m; p=0.022).
Collagen type VI coverage and thickness decreased (p<0.001 and p=0.005, respectively) with development of processes. Abnormal chon-
drocytes in macroscopically nondegenerate cartilage demonstrated a marked increase in IL-1 and loss of pericellular type VI collagen,
changes that could lead to cartilage degeneration. © 2010 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J. Orthop.
Res. 28: 1507–1514, 2010
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Osteoarthritis (OA) is a complex disorder involving
articular cartilage degeneration of diarthrodial joints1
in which changes to matrix metabolism by chondrocytes
are pivotal.2,3 Alterations to the balance betweenmatrix
synthesis/breakdown occur,2,3 but as degeneration is
slow, early changes are difﬁcult to identify. However,
the study of chondrocytes in nondegenerate cartilage
could be productive.4 Using single and 2-photon laser
scanning microscopy (2PLSM),5,6 we have shown that
the morphology of living in situ chondrocytes in rela-
tively nondegenerate (grade 0/1) tibial plateau cartilage
is complex. The elliptical shape of superﬁcial zone (SZ)
cells was evident, in addition to rounded forms in mid
and deep zones (MZ, DZ). However, a proportion (∼40%)
of cells was abnormal with cytoplasmic processes5 an
observation conﬁrmed by others also reporting abnor-
mal human chondrocytes.7−9 These processes differ from
the primary cilia observed in articular chondrocytes
as the latter are shorter (∼1m) requiring speciﬁc
cytoskeletal labeling.10
Chondrocytes are phenotypically unstable11 and
demonstrate a close relationship between shape and
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matrix metabolism. For example, chondrocytes in 3D
culture synthesize cartilage-speciﬁc macromolecules
(type II collagen, aggrecan12,13) but if the cell–matrix
interaction is modiﬁed (e.g., in 2D culture), changes
to a ﬁbroblastic phenotype occur12 with alterations
to matrix metabolism (increased collagen type I and
small proteoglycan production).12−14 In 3D cultures, de-
differentiated cells revert to the chondrocytic phenotype
with recovery in synthesis of cartilage-speciﬁc macro-
molecules.14 Thus chondrocytes with abnormal mor-
phology could be associated with deleterious changes to
matrix metabolism, potentially leading to OA.
ECM breakdown in OA is largely mediated by
raised levels of pro-inﬂammatory cytokines (e.g., IL-
1 and TNF-) and mediators, which stimulate
the synthesis/release of degradative enzymes2,3 and
inhibit aggrecan/collagen synthesis.15,16 IL-1 is highly
expressed by chondrocytes and in synovial ﬂuid of OA
joints17,18 and it induces cartilage damage, for example,
by elevating matrix metalloproteinases (MMPs).2,3,19,20
Changes to levels of cytokines/degradative enzymes
alter the pericellular matrix (PCM; “chondron”21)
around chondrocytes. This can be determined by study-
ing collagen type VI which is exclusively localized to the
PCM in nondegenerate cartilage22−24 and deﬁnes the
extent/integrity of the chondron.22 Accumulation of col-
lagen typeVI around human chondrocytes is suppressed
by IL-125 and disrupted in OA.24−26
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We investigated whether abnormal chondrocyte mor-
phology in relatively nondegenerate cartilage5 was
related to increased levels of cell-associated IL-1. As
IL-1 is linked to matrix breakdown,15,16 we also mea-
sured collagen type VI distribution to assess the PCM
of abnormal chondrocytes. We incubated osteochon-
dral explants of human tibial plateau cartilage graded
0 or 15 with a vital ﬂuorescent dye to label in situ
cells. Using CLSM/2PLSM and image analysis,5,6,27 we
recorded ﬁne cell shape to discriminate between normal
(elliptical/rounded) or abnormally shaped chondrocytes
(i.e., with >1 cytoplasmic processes/cell). Using ﬂuores-
cence immuno-histochemistry (FI) on the same cells,
we visualized IL-1 labeling and PCM collagen type
VI. FI was quantiﬁed to statistically compare labeling
between cells of varying morphology. IL-1 levels were
markedly elevated in abnormal cells, with collagen type
VI coverage/thickness reduced compared to normal cells.
This suggests that abnormal chondrocytes in relatively
nondegenerate cartilage are associated with marked
changes to levels of a cytokine implicated in OA and
their PCM was compromised.
MATERIALS AND METHODS
Biochemicals
CellTrackerTM Blue (CTB) was from Invitrogen (Paisley, UK).
Optimal cutting temperature compound (OCTC) was from
R. Lamb Ltd (Eastbourne, UK). Rabbit monoclonal anti-
IL-1 (1:200 in PBS) and rabbit polyclonal anti-collagen
type VI (1:50) were from Abcam (Cambridge, UK). Fluores-
cently tagged secondary antibody (2◦Ab) goat anti-rabbit IgG
Alexa Fluor 546 (1:50) was from Invitrogen. Fluosave was
from Calbiochem (Beeston, UK) and other biochemicals from
Sigma–Aldrich (Poole, UK).
Human Cartilage
Tissue was obtained with ethical permission from the tibial
plateau of 21 patients (13 males and 8 females; range 49–86
years; 68.4±2.3 years) undergoing total knee arthroplasty.
Excised joints showed various stages of OA and were graded
as described.5 Only tibial plateau cartilage with intact SZ
(grades 0/1) and underlying bone attached was used. Tissue
blocks were trimmed to ∼2mm×5mm×5mm,28 then incu-
bated in DMEM with CTB (5M; 2h; 37◦C) to ﬂuorescently
label live in situ chondrocytes. Samples were snap-frozen in
freezing hexane (−80◦C), sections cut (25m; −25◦C) using
OCTC, mounted on silane-coated slides, and stored (−80◦C)
until required.
Fluorescence Immuno-Histochemistry
For IL-1, sections were air-dried before antigen retrieval8
then washed (PBS; 3×5min) and permeabilized (Triton X-
100 0.5%; 5min; 21◦C). After 6× further washes, nonspeciﬁc
2◦Abbindingwas blockedwith serum from the 2◦Abproduction
host species. For collagen type VI, antigen retrieval was not
required and nonspeciﬁc 2◦Ab binding was blocked as above.
Staining was performed with the 1◦Ab (2h; 37◦C), washed and
incubated with the 2◦Ab (1h; 37◦C). After a ﬁnal wash, sam-
ples were mounted (Fluosave) and stored (4◦C) until imaged.
Controls were treated as above except for the 1◦Ab, which was
replaced with serum from the 1◦Ab production host species
and these showed no detectable ﬂuorescence (data not shown).
The best 1◦Abs trialed for both IL-1 and the collagen were
from the same host species making dual FI impossible. Con-
trols showed speciﬁc IL-1 labeling to normal human synovial
cells was undetectable, butmarkedly increased in inﬂamed tis-
sue (data not shown). Collagen type VI labeling was speciﬁc to
the PCM22−26 (data not shown; see Fig. 4).
CLSM/2PLSM Image Acquisition and Analysis of Fluorescently
Labeled Proteins
A Zeiss Axioskop LSM510 (Welwyn Garden City, UK)
with Verdi/Mira pulsed laser (Coherent, Inc., Santa Clara,
CA) and 63× water immersion (NA=1.2) or 10× dry
(NA=0.3) objectives were used to obtain images of CTB
(cell morphology5,6) and Alexa Fluor 546 (IL-1/collagen
type VI-associated ﬂuorescence). For CTB, Ex=780nm (2-P
excitation6), Em=435–485nm; for Alexa Fluor, Ex=543nm,
Em=560nm. z-Axis increments were typically 1m and
image quality optimized.5,6 Morphology was recorded in 3D
(VolocityTM, Perkin Elmer, Cambridge, UK). Cytoplasmic pro-
cesses yielded low ﬂuorescence compared to the cell body at low
magniﬁcation (Fig. 1a); however, at high power, ﬁne processes
were easily identiﬁed (Fig. 1b). We inspected each optical sec-
tion, then traced, andmeasured their length and number in 3D
of single cells by eye. Chondrocytes with “normal” morphology
exhibited a “smooth” membrane surface, whereas “abnormal”
cells were deﬁned as demonstrating >1 cytoplasmic process.
Abnormal chondrocytes were further classiﬁed by the number
and average length of cytoplasmic processes per cell. Usually
only cells in the center of a section, with processes <8m
from the cell body in the z-axis could be analyzed precisely.
For longer processes, accurate lengths were obtained in x
and y. Our protocols under, rather than over-estimated the
number/length of processes for cells at the edges of sections.
Fluorescent IL-1 labeling was determined on a per cell basis
using VolocityTM. Unbiased selection of cells was performed
by taking a point of intense CTB ﬂuorescence within the cell’s
center, with adjacent voxels (3D pixels) selected if within∼40%
of the point intensity. Voxels of anti-IL-1-associated ﬂuores-
cence were only counted if co-localized with CTB and above
threshold (Fig. 1c,d), which was established from the maxi-
mum voxel intensity of AlexaFluor for all cells in the negative
controls, imaged using identical parameters to the positively
stained sections. Thus, only IL-1-associated ﬂuorescence
co-localizing with CTB (and thus chondrocyte-associated) was
used in our analysis. For collagen type VI, single CTB-labeled
cells were identiﬁed, and Ab staining measured for thick-
ness/degree of coverage. A cross hair was placed over the cell
andwhere the lines intersected the ﬂuorescence, thicknesswas
measured and averaged (Fig. 4a). The number of intersections
(0–4) identiﬁed the degree of encapsulation (0–100%).
Statistics
The study was performed on 21 subjects who contributed one
joint each (i.e., n=21).N represented the total number of chon-
drocytes studied at each condition and data are presented as
mean±SEM for [n (N)]. Statistical tests were performed using
Sigma Stat (Systat, Inc., San Jose, CA). Unpaired Student’s
t-test and Mann–Whitney rank sum test (indicated with a
single asterisk, *) were used to compare normally and nonnor-
mally distributed data, respectively. Trends were analyzed by
least-squares regression andKruskal–Wallis one-wayANOVA.
Resulting p-values are indicated and considered signiﬁcant at
p<0.05.
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Figure 1. Cell morphology and quantiﬁcation of cell-associated IL-1 ﬂuorescence. Image (a) shows a cell labeled with CellTrackerTM
Blue (CTB; shown white for identiﬁcation) selected from a ﬁeld of view taken at low magniﬁcation (bar=50m). This cell is shown at
higher magniﬁcation (image (b); bar= 10m) with morphology (number and average length of cytoplasmic processes) of the CTB-labeled
chondrocyte determined by lines drawn along processes in a 3D projected image measured by VolocityTM. The cell was then isolated as a
region of interest (ROI) by selecting a point of intense immuno-ﬂuorescence within the cell’s center (image (c)) and adjacent voxels included
as part of the cell if within 40% of the CTB signal with the ROI shown with associated immuno-ﬂuorescence. IL-1 immuno-ﬂuorescence
was subjected to an intensity threshold (image (d)) determined from in situ chondrocytes on control slides and the remaining positive
voxels reported using VolocityTM. Examples of IL-1 ﬂuorescence immuno-histochemistry in cells with varying morphology are shown
(images (e–h); bar for all =10m). CTB ﬂuorescence was shown white with IL-1 immuno-ﬂuorescent positive voxels overlaid in red.
In image (e), a normal SZ chondrocyte is shown, with negligible levels of cell-associated IL-1 immuno-ﬂuorescence, whereas the SZ cell
shown in (f) was abnormal and demonstrated marked IL-1 labeling. A normal DZ chondrocyte is also shown with no detectable IL-1
labeling (image (g)), and image (h) illustrates an abnormal DZ chondrocyte with a cytoplasmic process and clear IL-1 labeling.
RESULTS
Sample Population and Cartilage Quality
Many tibial plateaus were screened with only 21 joints
having sufﬁciently large areas on gross inspection to
be nondegenerate. After microscopic examination of the
surface, only the cartilage from areas of two joints was
grade 0, with the rest being grade 1, that is, some surface
roughness but no loss of SZ chondrocytes.5 Thus, grade
0 and 1 cartilages were considered nondegenerate and
the data pooled.
Morphology of In Situ Human Chondrocytes
Chondrocyte heterogeneity can only be fully appreci-
ated using ﬂuorescent labeling and CLSM/2PLSM.5,6,27
The number (1–9) and length (∼1 to ∼40m) of the
processes varied markedly. Morphology was classiﬁed
as either normal (elliptical/spheroidal) with a “smooth”
surface, or abnormal, that is, a chondrocyte with one
or more cytoplasmic processes. Of the 677 cells exam-
ined, 311 (∼46%) exhibitednormal roundedmorphology;
however, we actively sought out morphologically abnor-
mal cells so that the full range of morphology could be
represented and the relationship between shape and
cell-associated IL-1 and collagen VI levels determined.
Abnormal cells were deﬁned as having one or more cyto-
plasmic processes. These cells were further classiﬁed on
the basis of the number/average length of processes per
cell. The groups for the number of processes/cell ranged
from none (P0; normal morphology), one (P1), two (P2),
three (P3), four (P4), and ﬁve (P5). Cells with P>6 were
observed, but not in a sufﬁcient number of indepen-
dent joints for evaluation. Classiﬁcation was also based
on the average length of the cytoplasmic processes/cell,
and grouped as; L0 (normal morphology), L5 (≤5m),
L10 (5–10m), L15 (10–15m), and L>15 (>15m). This
classiﬁcation underestimated the variety of cell shapes
present; however they were appropriate groupings for
this study.
Chondrocyte Morphology and Cell-Associated IL-1
Figure 1e–h shows examples of normal and abnormal
cells in the SZ and DZ with IL-1 levels identiﬁed by
FI. By counting the number of positively stained voxels
(i.e., 3D pixels containing ﬂuorescence above baseline),
we statistically compared cell-associated IL-1 ﬂuores-
cence for cells of different morphology. MZ chondrocytes
were not analyzed as they were difﬁcult to identify
as there was often not a clear demarcation between
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Figure 2. IL-1 immuno-ﬂuorescence associated with normal or
abnormal cells in the superﬁcial zone (SZ) or deep zone (DZ). There
was signiﬁcantly greater IL-1 ﬂuorescence in morphologically
abnormal chondrocytes (i.e., cellswith one ormore cytoplasmic pro-
cess) compared to normal cells in both the SZ and DZ. There was
no difference between normal or abnormal cells in the two zones
(p=0.354, 0.513). Data as means±SEM for [n (N)] and compared
using unpaired Student’s t-tests.
zones.29 IL-1 labeling increased for abnormal cells in
both SZ and DZ (Fig. 2; p=0.04 and 0.006) whereas
there was no difference between normal (p=0.354) or
abnormal cells (p=0.513) in the two zones suggesting
abnormal morphology determined IL-1 levels rather
than the zone in which the chondrocyte resided. When
the numbers of processes/cell were compared, there was
a signiﬁcant (∼270+ve voxels/cell process) linear corre-
lation (Fig. 3a). Cells in groups P2–P5 had more positive
voxels than normal cells (p=0.05 for P2; p=0.003 for P3,
P4, and P5). When IL-1 FI was compared between cells
grouped by average process length (Fig. 3b), there was
an increase for L5, L10, and L15 (p=0.022, 0.026, 0.047).
However, IL-1 levels decreased with average length of
processes from L5 to L15. For L>15 cells, there was no
difference compared to normal (p=0.753) although the
number of joints and cells in this group was small and
the error large. Thus abnormal chondrocytes, particu-
larly those with >2 processes/cell, and those where the
average length of the processes was ≤5m had higher
levels of cell-associated IL-1 labeling compared to nor-
mal cells.
Collagen Type VI and Chondrocyte Morphology
SZ cells were studied as the full range of shapes was
present, and labeling performed in parallel with assess-
ment of chondrocyte shape. Figure 4a shows a normal
cell beside an abnormal chondrocyte, with very different
collagen type VI levels (∼100% vs. ∼0%) as the nor-
mal cell was surrounded whereas the abnormal cell was
devoid of this collagen. The method for assessing colla-
gen type VI encapsulation and thickness around in situ
chondrocytes is also shown with examples of a cell with
(b) ∼75% and (c) ∼50% encapsulation. Collagen type VI
almost completely (88.4±5.53%; Fig. 5a,b) surrounded
Figure 3. IL-1 immuno-ﬂuorescence as a function of chon-
drocyte morphology. Cell morphology was categorized by (a)
the number of processes/cell and levels of cell-associated IL-
1 ﬂuorescence determined. IL-1 labeling increased with the
number of processes (linear regression; r2 =0.988). IL-1 immuno-
ﬂuorescence was signiﬁcantly higher compared to control (P0) for
P2–P5 cells. Morphology was also categorized by (b) the average
length of processes/cell and IL-1 levels were signiﬁcantly higher
for cells up to L15 compared to normal (L0), but not for L>15 cells
(p=0.753). Data were compared using unpaired Student’s t-tests.
normal cells. There was a reduction in type VI enclo-
sure when morphology was classiﬁed by the number of
processes (Fig. 5a). P1 cells had ∼50% of the type VI col-
lagen of P0 cells (p=0.006); however, for cells with >1
process, there was no further decrease (p=0.2). There
was a large reduction in collagen coverage as the aver-
age process length increased (L5–L10 and L15; p<0.001
by ANOVA; Fig. 5b). Collagen type VI thickness declined
with number of cytoplasmic processes/cell and reached
a lower level (P2, P3, and P4; p=0.001, 0.001, and
0.033; Fig. 5c) compared to normal cells. Abnormal
cells showed reduced (p=0.011) collagen thickness with
average process length for L5, but the decrease for L10
cells was not quite signiﬁcant (p=0.062; Fig. 5d).
DISCUSSION
This study extends previous work5,15,16 by showing
that abnormal morphology of in situ human chondro-
cytes in relatively nondegenerate load-bearing articular
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Figure 4. Examples and assessment of collagen type VI labeling-
associated ﬂuorescence with in situ chondrocytes. Collagen around
single chondrocytes was analyzed by overlaying vertical/ hori-
zontal lines (green overlay, (a)), on projected images meeting at
the cell center. The number of line intersections (0–4) with col-
lagen staining was recorded as a measure of encapsulation. At
each intersection, the thickness of collagen staining was measured
perpendicular to the stained edge. Labeling is shown completely
(∼100%) enclosing a normal cell (a), or absent from an adjacent
abnormal cell (∼0%), or surrounding (b) ∼75%, or (c) ∼50% of
abnormal cells (bar = 10m).
cartilage was associated with increased IL-1 levels
particularly in chondrocytes with many processes/cell
(Fig. 3a) and when the processes were short (Fig. 3b).
Our relatively novel approach for FI quantiﬁcation
permitted a statistical analysis of cell-associated Ab
labeling. Collagen type VI coverage was reduced in
abnormal chondrocytes especially those with a large
average length of processes (Fig. 5). The results sug-
gested that changes to human chondrocyte morphology
occur in relatively nondegenerate cartilagewithmarked
effects on cell-associated levels of IL-1 and collagen
type VI of the PCM.
We used aged and relatively nondegenerate cartilage,
which might not be exactly comparable to “normal” tis-
sue as it was taken from discrete areas of failed joints.
Care was taken to ensure only load-bearing grade 0/1
areas were studied. Obtaining grade 0 human cartilage
can be difﬁcult; however, since OA is focal with adjacent
nondegenerate areas, we used the present approach.4
We only had access to two grade 0 samples, and for
some of the others it was difﬁcult to determine if they
were grade 0 or 1. Thus, we pooled this tissue, so
the crucial comparison was between the range of cell
shapes rather than cartilage grades. It might be thought
there would be an inverse relationship between % nor-
mal chondrocytes and patient age. Although the age
range (49–86 years) and patient number (21) was lim-
ited, there was no change (r2 =−0.088±0.141% normal
cells/year; slope N/S; p=0.5). In addition, IL-1 levels
increased in abnormal cells (Figs. 2 and 3), and this
cytokine induces changes to matrix metabolism in com-
plete contrast to those occurring in aged cartilage.30
Although we detected very low levels of cell-
associated IL-1 in normal chondrocytes (∼100 vox-
els/cell; Figs. 2 and 3) we regard this as a negligi-
ble/baseline level. Of all the 320 cells studied (Fig. 3a)
only 25% had signiﬁcant IL-1 labeling, but this was
not a quarter of all cells in cartilage. These highly
abnormal cells (>3 processes) were only a small % of
the population and almost all were in the SZ, where
IL-1 levels were highest.16 We actively sought out
abnormal cells and thus this does not represent the
whole cell population. Furthermore, the % of abnormal
cells in the DZ of grade 0/1 cartilage was low (typi-
cally ∼5%) compared to the SZ; however, IL-1 levels
were elevated to the same extent as abnormal cells
in the SZ (Fig. 2). Thus, cell shape and not cartilage
zone determined IL-1 levels. An important question is
whether the IL-1 of abnormal chondrocytes was locally
expressed in an auto-/paracrine manner, or whether it
primarily originated from synovial ﬂuid. Levels of IL-1
in synovial ﬂuid rise markedly during OA,17 and this,
with the increased permeability of a weakened matrix,
could increase levels in the SZ and around chondro-
cytes. This cytokine could stimulate IL-1 expression
and this taken with the higher levels of the cytokine
receptor (IL-1R1) in chondrocytes from OA patients31
raises the possibility that abnormal chondrocytes bind
more IL-1. It is possible that both sources of IL-1
could be involved although their relative contributions
are unclear. However, in preliminary experiments (A.C.
Hall, P.G. Bush, unpublished work) where we have incu-
bated cartilage explants for up to 2 weeks with high
levels of IL-1 (50 ng/ml) compared to those found in
synovial ﬂuid of OA patients,17 we have not observed
abnormal chondrocytemorphology. Thus, althoughmore
work is clearly required, we think it is unlikely that the
abnormal chondrocytes observed in the present study
arise from normal chondrocytes exposed to exogenous
IL-1.
Irrespective of the origin of the IL-1, this cytokine
could stimulate autocrine response(s) and signaling
cascades leading to local release/activation of matrix-
degrading enzymes (MMPs, ADAMTS2,19,20,32−34) caus-
ing a weakened matrix through which processes
develop, similar to the proteolysis of cell invasion
through the ECM.35 Alternatively, abnormal cells
could result from mechanical damage to collagen type
VI-PCM integrity23 leading to reduced cell–matrix
interactions.23,36 Loss of this collagen could enhance
chondrocyte migration through gaps in the chondron
capsule.37 A close relationship exists between cell
shape, expression of matrix constituents and degrada-
tive enzymes.11−14 However, the role of IL-1 is unclear
as it could also be involved inmatrix anabolism/repair.38
The association between abnormal chondrocytes, ﬁbrob-
lastic phenotype, andmatrix turnover11−14 is important.
However, techniques for visualizing/categorizing in situ
chondrocyte shape and correlating this with quantita-
tive levels of ﬂuorescently labeled proteins are not trivial
requiring further development, with concerns including
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Figure 5. Collagen type VI associated with SZ chondrocytes of varying morphology. The % of collagen type VI around cells is shown in
relation to (a) the number of processes/cell or (b) the average length of processes/cell. For P1–4 there was a reduction in % encapsulation
with number of processes/cell compared to P0 cells (p=0.006 or less) but no difference between groups of increasingly abnormal cells
(p=0.2; ANOVA). Compared to L0 cells (b), there was a decrease for all groups (p=0.003 or less) and L10 and L15 cells exhibited a
reduction compared to L5 cells (p=0.022 and 0.009, respectively). The lower panels show collagen thickness around normal/abnormal
chondrocytes (number of processes/cell, c) or average length of processes/cell (d). Collagen thickness (c) was reduced for P2–4 compared to
P0 cells. L5 cells showed a reduction (p=0.011) compared to L0 but the decrease for L10 was not signiﬁcant (p=0.062). Data were shown
as means±SEM for [n (N)] and compared by unpaired Student’s t-tests, or Mann–Whitney rank sum tests (indicated by *).
the CLSM system/imaging software, methods for quan-
tiﬁcation, Ab speciﬁcity, and antigen retrieval.
Reduced collagen type VI thickness/coverage (Fig. 5)
could be important for abnormal chondrocyte devel-
opment in macroscopically nondegenerate cartilage.
Interestingly, in the collagen type VI knockout mouse,
the PCM develops normally but has reduced stiffness
prior to the onset of histological changes associated
withOA.39 Although changes to cell–matrix interactions
probably occur, early events relating changes to PCM,
cell shape, and IL-1 levels are unknown. Our data sug-
gest that levels of cell-associated IL-1 are higher in
abnormal cells when the average length of the processes
was≤5m (Fig. 3b) and these cells had reduced collagen
type VI encapsulation (Fig. 5b). Early PCM weakening
could lead to a loss of chondrocyte–matrix interactions
and development of multiple short processes, raising
levels of cell-associated IL-1 compared to when the
average length of processes is longer (Fig. 3b). Increased
cytokine levels would stimulate the release of degrada-
tive enzymes2 leading to further PCM breakdown and
focal areas of weakness around chondrocytes through
which the development of a small number of larger cyto-
plasmic processes develops. Once the processes break
out of the PCM, then the ability of the chondrocyte
to maintain the PCM decreases leading to increased
loss of collagen type VI (Fig. 5b). With our methods we
cannot determine if the chondrocytes with cytoplasmic
processes are on the point of dying but it is possible these
cells are more sensitive to mechanical loading compared
to normal rounded/ellipsoidal chondrocytes.
Caution should however be applied when compar-
ing our collagen type VI data to previous work, as we
used grade 0/1 cartilage and labeling was related to cell
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morphology in contrast to the generalized changes in
severely degenerate cartilage (grade 2–3) with chondro-
cyte clusters.24−26 These studies showed increased type
VI collagen synthesis by cells in the lowerMZ/upper DZ,
whereas there was a loss in the upper MZ24,26 possibly
related to PCM remodeling with chondrocyte prolifera-
tion/clustering in late OA.24−26 A previous study26 noted
viable “exceptional” chondrocytes with low collagen type
VI, and it is possible that these were abnormally shaped
cells (Fig. 5). In summary, abnormal in situ chondrocyte
morphology in relatively nondegenerate human carti-
lage was associated with increased cell-associated IL-1
levels and loss of pericellular collagen type VI struc-
ture. A future challengewill be to clarify the relationship
between in situ human chondrocyte morphology, pheno-
type, and matrix metabolism.
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